Traditional Validation - Downstream

Similar documents
Workshop on process validation

Process Validation: Practical Aspects of the New FDA Guidance

Workshop on process validation

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

White paper: FDA Guidance for Industry Update Process Validation

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Validation and Calibration. Definitions and Terminology

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

Manufacturing process of biologics

Guidance on Qualification of existing facilities, systems, equipment and utilities

Quality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party

Implementing New USP Chapters for Analytical Method Validation

OPERATIONAL STANDARD

FDA Guidance for Industry Update - Process Validation

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *

Guidance for Industry

IMPURITIES IN NEW DRUG PRODUCTS

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.

Impact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11

Guidance for Industry

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

What to control? CQAs and CPPs

Lifecycle CMC Management: ICH Q12 Progress to date

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

Control Strategy Case Studies

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

Guidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing

Workshop A Design Space (DS)

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS

What is Process Validation?

Biomanufacturing Vision for the Future

Bioprocessing Media and Buffers Grow with Us

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015

Guideline on Process Validation

CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS

Workshop B Control Strategy

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Why System Suitability Tests Are Not a Substitute for Analytical Instrument Qualification

Gamma Sterilisation Validation according to ISO Sterilising dose -

Marmara Üniversitesi Fen-Edebiyat Fakültesi Kimya Bölümü / Biyokimya Anabilim Dalı PURIFICATION AND CHARACTERIZATION OF PROTEINS

Innovation and Progress in Water Treatment Technology

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

XPure. Simulated Moving Bed. System for Chromatography and Ion exchange applications. Better solutions for your purification needs

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION

Working with ICH Quality Guidelines - the Canadian Perspective

Biopharmaceutical Process Evaluated for Viral Clearance

A novel AIEX chromatography medium (resin) to remove IgA and IVIG purification process

Technology Transfer of CMC Activities for MAb Manufacturing ge healthcare (

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015

Specific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004

The Importance of Developing a High Yield of Product

Customer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

Guide to Reverse Phase SpinColumns Chromatography for Sample Prep

Zeta Automation. Automation for pharma industry.

Recent Updates on European Requirements and what QPs are expected to do

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

Data Mining Builds Process Understanding for Vaccine Manufacturing

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

Viral Safety of Plasma-Derived Products

Computerised Systems. Seeing the Wood from the Trees

PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY

ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK

Design Verification The Case for Verification, Not Validation

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

Assay Qualification Template for Host Cell Protein ELISA

PHARMACEUTICAL OUTSOURCING:

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7

Hazard Analysis and Critical Control Points (HACCP) 1 Overview

Wastewater Reuse. Typical treated wastewater is:

Valentina Gualato, Ph.D. Process Development Scientist

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations

A new, integrated, continuous purification process template for monoclonal antibodies

Differentiation Summary. Revolutionizing Water Clean-Up Opportunities

Design of Experiments for Analytical Method Development and Validation

Testing Automated Manufacturing Processes

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Process-scale purification of monoclonal antibodies polishing using Capto Q

Biotechpharma company profile

Internal Quality Management System Audit Checklist (ISO9001:2015) Q# ISO 9001:2015 Clause Audit Question Audit Evidence 4 Context of the Organization

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

Risk Management for Aseptic Processing

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography

Application Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

Applications of Organic Solvent Nanofiltration in the Process Development of Active Pharmaceutical Ingredients. Dominic Ormerod

Transcription:

EMA Expert Workshop on Validation of Manufacturing for Biological Medicinal Products Tuesday 9 th April 2013 Traditional Validation - Downstream Marco Strohmeier

Topics of the Presentation What is the Industry understanding of "process performance indicators and parameters for the downstream processes? Are there any differences/similarity of this terminology compared with "material attributes", "consistency indicators/parameters"? Which indicators or parameters should be presented in the Marketing Authorisation. Application (MAA) to support process validation? In case of single-use equipments or facilities, what are the main differences between process validation studies and studies to qualify these equipments and facilities? Multi-facility production: - What are the key elements in validation when a process gets transferred from one site (site 1) to another site (site 2). - How is a diversification of the product which might be caused by process changes at both sites during product life cycle time prevented. And how is comparability achieved and maintained? How to evaluate and verify reliability/predictability of small-scale models for the upstream and downstream processes?

Question 1 What is the Industry understanding of "process performance indicators and parameters for the downstream processes? Are there any differences/similarity of this terminology compared with "material attributes", "consistency indicators/parameters"? Which indicators or parameters should be presented in the Marketing Authorisation. Application (MAA) to support process validation?

Parameter and Indicator - Process Parameter Defined during development and scale-up - Operation of Chromatography, membrane steps etc., - Product stream conditions (ph, cond), if directly controlled Experiments are established to link process parameters, potential variability and product CQAs Control strategy has to be developed Process Parameters and associated control strategy, that impact CQAs are included in MAA Process performance indicators and parameters that don t impact CQA s do not need to be included as regulatory commitments in the MAA.

Parameter and Indicator - Process Performance Indicators Defined during development and scale-up - Example: Step yield and overall yield Process performance indicators are not direct measures of product quality but are measures of process performance and consistency DOEs are established to link process parameter with process performance indicators Process performance and consistency also has a developed control strategy Process performance indicators and associated control strategy, that are important to understand process performance and consistency are described in MAA but are not considered as regulatory commitments. They are handled internally via the company quality systems.

Parameter and Indicator - Material Attributes Material attributes that are not part of the control strategy should not be submitted in the MAA but maintained under the review of the companies quality system Examples of controlled and non controlled material attributes - Pore size of a SEC controlled - Ion binding capacity of a Ion Binder not controlled

Question 2 In case of single-use equipments or facilities, what are the main differences between process validation studies and studies to qualify these equipments and facilities?

Single-use Equipment - Definitions <Process Validation> (ICH Q7A, D. Approaches to Process Validation) Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes. <Qualification> (ICH Q7A, C. Qualification) Before initiating process validation, appropriate qualification of critical equipment and ancillary systems should be completed

Single-use Equipment - Qualification and Validation Qualification: Finalize <qualification> working package acc. to ICH guideline (DQ, IQ, OQ, PQ) Outcome of qualification effort is related to facility (stainless steel and/or disposable independent from any potential product Qualification is a mandatory activity before starting PV With no changes, qualification is a singular activity independent from number of processes to be validated <Equipment Qualification> is not considered to be part of the process validation package

Single-use Equipment - Qualification and Validation Validation Finalize <process validation> working package acc. to ICH guideline Outcome is related to dedicated process in a qualified environment Process parameter ranges have to be within the ranges defined and checked in equipment qualification (e.g. flow of a pump in DSP, mixing speed etc.) Obvious difference <stainless steel> vs. <single-use equipment> No need for cleaning validation for <single-use equipment>

: Single-use Equipment - Leachables and Extractables Additional efforts to be considered in MAA using single-use equipment Leachables/Extractables studies Elements in MAA List of all disposable material used at different steps Duration of product/intermediate contact with disposable material incl. worst case assumptions Risk assessement regarding impact on quality target product profile Detectability is low Discriminate early stage and late stage process steps in purification Impact on removability of leachables Design and result of studies (final report)

Question 3 Multi-facility production: What are the key elements in validation when a process gets transferred from one site (site 1) to another site (site 2). How is a diversification of the Processes prevented which might be caused by process changes at both sites during process life time. And how is comparability archived and maintained?

Process transfer Elements and Principles Site 1 Site 2 Process Validation elements of Site 1 Bio Purification Scale down Modle qualification Stability of intermendiates Buffer stability Extractebles and Leachables Mixing/Homogenisation Impurity removal and carry over Validation of Prozess parameter (Chromatography, Filtration, Ultrafiltration parameter) Cycle no of Media/Membranes Regeneration and desinfection Media/Membrane storage Transfer Only for identical sites the validation results of site 1 are applicable also for site 2 BUT Sites are rarely identical Thus Differences have to be assessed with Subsequent verification of validation status and comparability Process Validation elements of Site 2 Bio Purification Scale down Modle qualification Stability of intermendiates Buffer stability Extractebles and Leachables Mixing/Homogenisation Impurity removal and carry over Validation of Prozess parameter (Chromatography, Filtration, Ultrafiltration parameter) Cycle no of Media/Membranes Regeneration and desinfection Media/Membrane storage

Example - Activities to Assess the Differences during process transfer Example of a Transfer Process Documentation transfer Gap Analysis and Change control Analytical transfer Production of batches at new site Reports and change control authorization Process and Product information from Donor Activity: GAP-Analysis Transfer of analytical methods Activity: Validation batches Activity: Evaluation of acceptance criteria Activity: Risk assesment on differenzes Output: PVReport Activity: Close change records Traslation into site specific process description by receiving site Activity: Including cleaning evaluation into riskassesment Output: Comparability Outputs: Transfer summary report Activity: Facility and process changes Grand of Changes Output: Risk management report Output: Change records Output: Prozess validation plans and protocolls Examples on potential differences to be assessed: Membranes Influence on product and small molecule removal Product concentration Influence on product Pressures during filtration Filter performance; Influence on Productquality

Multi-facility Production - Comparability and Diversification Comparabilty is shown by: Meaningfull statistical methods Extended Measurements during validation runs at site 2 Extend is case specific and depends on GAP analysis and risk assesment. Diversification by process changes can be prevented by: Change management Meaningfull specification of raw materials (material attributes) and raw material testing? Continous and/or periodic (statistical found) process monitoring at each site

Question 4 How to evaluate and verify reliability/predictability of small-scale models for the upstream and downstream processes? - Mainly adressed in the Upstream and the Advanced Process Validation presentations Principles for small scale models with respect to the traditional approach are presented here

Small Scale Models Variety of applications for validation of down stream processes Evaluation of conditions that are difficult or impossible to be studied at manufacturing scale Two types of Models Full: miniaturized versions of the manufacturing scale process (-step). Example: - Chromatography models employed under manufacturing target conditions Partial: aspects of the at scale system are modeled, typically to isolate or exaggerate a condition. Example: - Intermediate hold time study models vessel surface area to volume ratio, temperature, and time may be exaggerated at small scale beyond the manufacturing conditions to evaluate a challenge condition

Applications of Small Scale Models Purpose Model Type Conditions Viral clearance Chromatography Full model Target Virus Filtration Full model Load challenge Low ph Inactivation Partial model ph and temperature challenge DNA clearance Chromatography Full model Target Intermediate hold time Product hold vessel Partial model SA/V ratio, temperature, and time challenge Filter/product compatibility Filtration Partial model SA/V ratio challenge Chromatography resin lifetime (impact on virus/impurity clearance) Chromatography Full model Cycle number challenge Reprocessing : Re-filtration Filtration (micro-filtration or ultrafiltration) Partial model SA/V ratio challenge, number of refiltrations challenge Impurity spiking experiments Chromatography, filtration or ultrafiltration Full model Worst case Load

: Qualification of Small Scale Models Qualification of models should focus on the aspects of the model that are most required. - Full models: Typically compared to pilot, clinical or manufacturing scale data under target operating conditions Relevant parameters and materials are consistent between scales Quality attribute and performance measures are selected for comparison based on intent of use of the model and may be compared statistically Other measures may be compared qualitatively, (e.g. chromatographic profiles) - Partial models: Typically justified theoretically based on scientific and engineering principles - Typically discussed in Sections 3.2.S.2.6 or 3.2.A.2 of MAA Description of the model and justifications for its qualification - For traditional approach, models are typically qualified one time, in preparation for marketing authorization. - Post-approval process changes may require a model to be re-qualified.

Acknowledgement Slides have been prepared by: Kristopher Barnthouse - Janssen Pharmaceutical Companies of Johnson & Johnson Jürgen Bongs - Sanofi-Aventis Deutschland GmbH Richard Turner MedImmune Ronald Imhoff - Janssen Pharmaceutical Companies of Johnson & Johnson Marco Strohmeier Roche Diagnostics GmbH